News
RLYB
1.850
+16.35%
0.260
Rallybio’s RLYB212 Positioned to Transform FNAIT Prophylaxis Market, Analyst Maintains Buy Rating
TipRanks · 2d ago
Weekly Report: what happened at RLYB last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at RLYB last week (0311-0315)?
Weekly Report · 03/18 09:27
12 Health Care Stocks Moving In Friday's Pre-Market Session
Better Therapeutics (NASDAQ:BTTX) shares increased by 85.4% to $0.06 during Friday's pre-market session. Madrigal Pharmaceuticals shares moved upwards by 22.34%. Akebia Therapeutic and Rallybio both reported better than expected Q4 earnings.
Benzinga · 03/15 13:06
Rallybio’s Clinical Advancements and Solid Financials Earn a Buy Rating from Analyst Ritu Baral
TipRanks · 03/13 21:35
Rallybio Price Target Maintained With a $8.00/Share by JMP Securities
Dow Jones · 03/13 15:58
JMP Securities Reiterates Market Outperform on Rallybio, Maintains $8 Price Target
Benzinga · 03/13 15:49
Rallybio Price Target Cut to $9.00/Share From $12.00 by HC Wainwright & Co.
Dow Jones · 03/13 11:29
Rallybio Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/13 11:29
HC Wainwright & Co. Maintains Buy on Rallybio, Lowers Price Target to $9
Benzinga · 03/13 11:22
Buy Rating Affirmed for Rallybio on Strong Drug Pipeline and Market Potential
In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Rallybio (RLYB) with a price target of $9.00. The company is developing treatments for rare immune disorders. Kapoor’s optimism is partly derived from the potential market position of RLYB212.
TipRanks · 03/13 10:25
Buy Rating Affirmed for Rallybio on Promising FNAIT Treatment and Financial Stability
TipRanks · 03/12 21:55
Rallybio: Q4 Earnings Insights
Rallybio reported its Q4 earnings results on March 12. Rallybio missed estimated earnings by -9.0%. The company's revenue was down $0 from the same period last year. Last quarter the company beat on EPS by $0.06.
Benzinga · 03/12 21:05
Rallybio Corp: Current report
Press release · 03/12 14:12
Rallybio GAAP EPS of -$0.50
Seeking Alpha · 03/12 13:49
Rallybio Q4 EPS $(0.50) Misses $(0.46) Estimate
Benzinga · 03/12 12:12
BRIEF-Rallybio Q4 Net Income USD -20.242 Million
Reuters · 03/12 12:00
Weekly Report: what happened at RLYB last week (0304-0308)?
Weekly Report · 03/11 09:26
Weekly Report: what happened at RLYB last week (0226-0301)?
Weekly Report · 03/04 09:27
Weekly Report: what happened at RLYB last week (0219-0223)?
Weekly Report · 02/26 09:29
More
Webull provides a variety of real-time RLYB stock news. You can receive the latest news about Rallybio Corp through multiple platforms. This information may help you make smarter investment decisions.
About RLYB
Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical needs in the areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. It has two clinical-stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Its other product candidates include RLYB114, RLYB331 and ENPP1 Program. Its second C5 inhibitor, RLYB114, is a pegylated C5-targeted Affibody molecule with PK properties designed for the treatment of complement-mediated ophthalmic diseases. RLYB331 is for the treatment of severe anemia.